A Sandoz spokesperson confirmed to BioPharma Dive that the company conducted an internal assessment of its marketed products to come up with a list of “essential” drugs that could help patients infected with SARS-CoV-2. The list includes priority antibiotics, hospital care products and antivirals.
As for the price on these drugs, Sandoz will not increase list prices, decrease rebates or take “other actions that are in our control that will increase the cost of our commercial medications to healthcare systems,” according to the spokesperson, who added that the company intends to keep prices stable throughout the coronavirus epidemic.
